Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Astermark

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2021
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia BJan Astermark, Katharina Holstein, Yasmina L Abajas, et al.
European Journal of Haematology|June 1, 2011
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusionsHerman Nilsson-Ehle, Gunnar Birgegård, Jan Samuelsson, et al.
Therapeutic Advances in Hematology|April 8, 2022
International consensus recommendations on the management of people with haemophilia BDaniel P Hart, Davide Matino, Jan Astermark, et al.
Blood Advances|March 15, 2022
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitorsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Blood|August 25, 2019
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial resultsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Therapeutic Advances in Hematology|October 9, 2024
Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regionsJan Blatný, Jan Astermark, Cristina Catarino, et al.
Blood|January 28, 2012
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysisSamantha C Gouw, H Marijke van den Berg, Johannes Oldenburg, et al.
Blood Advances|June 24, 2026
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 studyGuy Young, Pantep Angchaisuksiri, Shashikant J Apte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndromeMichael Grövdal, Rasheed Khan, Anni Aggerholm, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 12, 2021
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia BJan Astermark, Katharina Holstein, Yasmina L Abajas, et al.
European Journal of Haematology|June 1, 2011
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusionsHerman Nilsson-Ehle, Gunnar Birgegård, Jan Samuelsson, et al.
Therapeutic Advances in Hematology|April 8, 2022
International consensus recommendations on the management of people with haemophilia BDaniel P Hart, Davide Matino, Jan Astermark, et al.
Blood Advances|March 15, 2022
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitorsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Blood|August 25, 2019
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial resultsAmy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, et al.
Therapeutic Advances in Hematology|October 9, 2024
Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regionsJan Blatný, Jan Astermark, Cristina Catarino, et al.
Blood|January 28, 2012
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysisSamantha C Gouw, H Marijke van den Berg, Johannes Oldenburg, et al.
Blood Advances|June 24, 2026
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 studyGuy Young, Pantep Angchaisuksiri, Shashikant J Apte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndromeMichael Grövdal, Rasheed Khan, Anni Aggerholm, et al.
Pageof 10